Hanna Jernberg, Marie Warrer Munch, Maj-Brit Nørregaard Kjær, Marie Helleberg, Morten Hylander Møller, Anders Perner
{"title":"Use of piperacillin/tazobactam and meropenem in a Danish intensive care unit.","authors":"Hanna Jernberg, Marie Warrer Munch, Maj-Brit Nørregaard Kjær, Marie Helleberg, Morten Hylander Møller, Anders Perner","doi":"10.61409/A02240081","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Intensive care unit (ICU) patients often have infections, and early empirical treatment with broad-spectrum antibiotics is recommended. As the choice between different agents is not supported by high-certainty evidence and as a part of a larger research programme, we aimed to describe the use of piperacillin/tazobactam (PTZ) and meropenem (MER) in patients in a university hospital ICU in Denmark and the patient outcomes of each of these treatments.</p><p><strong>Methods: </strong>We prospectively screened all patients admitted to the general 24-bed ICU at Rigshospitalet for 12 consecutive weeks as from 1 November 2022. Patients were included if they received PTZ or MER during their ICU stay. The primary outcome was 90-day mortality.</p><p><strong>Results: </strong>Among 286 patients, 184 (64%) received PTZ and/or MER; 112 (61%) were men, and 161 (88%) received life support. Among these, 80 (43%) received PTZ, 76 (41%) received MER and 28 (15%) received both agents, mainly as empirical treatment. At 90 days, 22 (28%) had died among patients receiving PTZ, 19 (26%) among those receiving MER and eight (29%) among those receiving both agents. At 90 days, 19 cases of a bacterium with new acquired resistance were identified in 17 of the 184 patients (9%) (eight cases among those receiving PTZ, five among those receiving MER, and six among those treated with both agents); vancomycin-resistant enterococci (VRE) accounted for 16 of the 19 cases.</p><p><strong>Conclusions: </strong>Most patients in the ICU of a Danish university hospital received antibiotic treatment with PTZ and/or MER, mainly as empirical treatment. Mortality and the occurrence of bacteria with new acquired resistance, mainly VRE, appeared to the same extent in the groups.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Not relevant.</p>","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"71 8","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A02240081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Intensive care unit (ICU) patients often have infections, and early empirical treatment with broad-spectrum antibiotics is recommended. As the choice between different agents is not supported by high-certainty evidence and as a part of a larger research programme, we aimed to describe the use of piperacillin/tazobactam (PTZ) and meropenem (MER) in patients in a university hospital ICU in Denmark and the patient outcomes of each of these treatments.
Methods: We prospectively screened all patients admitted to the general 24-bed ICU at Rigshospitalet for 12 consecutive weeks as from 1 November 2022. Patients were included if they received PTZ or MER during their ICU stay. The primary outcome was 90-day mortality.
Results: Among 286 patients, 184 (64%) received PTZ and/or MER; 112 (61%) were men, and 161 (88%) received life support. Among these, 80 (43%) received PTZ, 76 (41%) received MER and 28 (15%) received both agents, mainly as empirical treatment. At 90 days, 22 (28%) had died among patients receiving PTZ, 19 (26%) among those receiving MER and eight (29%) among those receiving both agents. At 90 days, 19 cases of a bacterium with new acquired resistance were identified in 17 of the 184 patients (9%) (eight cases among those receiving PTZ, five among those receiving MER, and six among those treated with both agents); vancomycin-resistant enterococci (VRE) accounted for 16 of the 19 cases.
Conclusions: Most patients in the ICU of a Danish university hospital received antibiotic treatment with PTZ and/or MER, mainly as empirical treatment. Mortality and the occurrence of bacteria with new acquired resistance, mainly VRE, appeared to the same extent in the groups.
期刊介绍：
The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content.
DMJ will publish the following articles:
• Original articles
• Protocol articles from large randomized clinical trials
• Systematic reviews and meta-analyses
• PhD theses from Danish faculties of health sciences
• DMSc theses from Danish faculties of health sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
